General Information of Drug Off-Target (DOT) (ID: OTPY0IH7)

DOT Name Advanced glycosylation end product-specific receptor (AGER)
Synonyms Receptor for advanced glycosylation end products
Gene Name AGER
UniProt ID
RAGE_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
2E5E; 2ENS; 2L7U; 2LE9; 2LMB; 2M1K; 2MJW; 2MOV; 3CJJ; 3O3U; 4LP4; 4LP5; 4OF5; 4OFV; 4OI7; 4OI8; 4P2Y; 4XYN; 4YBH; 5D7F; 6VXG; 6XQ1; 6XQ3; 6XQ5; 6XQ6; 6XQ7; 6XQ8; 6XQ9; 7LML; 7LMW
Pfam ID
PF08205 ; PF00047 ; PF13927
Sequence
MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEA
WKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQI
PGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRH
PETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQL
VVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYS
CVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGV
ILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP
Function
Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans. Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. These ligands accumulate at inflammatory sites during the pathogenesis of various diseases, including diabetes, vascular complications, neurodegenerative disorders, and cancers and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction or inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Participates in endothelial albumin transcytosis together with HMGB1 through the RAGE/SRC/Caveolin-1 pathway, leading to endothelial hyperpermeability. Mediates the loading of HMGB1 in extracellular vesicles (EVs) that shuttle HMGB1 to hepatocytes by transferrin-mediated endocytosis and subsequently promote hepatocyte pyroptosis by activating the NLRP3 inflammasome. Promotes also extracellular hypomethylated DNA (CpG DNA) uptake by cells via the endosomal route to activate inflammatory responses.
Tissue Specificity Endothelial cells.
KEGG Pathway
Efferocytosis (hsa04148 )
Neutrophil extracellular trap formation (hsa04613 )
AGE-RAGE sig.ling pathway in diabetic complications (hsa04933 )
Alzheimer disease (hsa05010 )
Pathways of neurodegeneration - multiple diseases (hsa05022 )
Diabetic cardiomyopathy (hsa05415 )
Lipid and atherosclerosis (hsa05417 )
Reactome Pathway
Advanced glycosylation endproduct receptor signaling (R-HSA-879415 )
TRAF6 mediated NF-kB activation (R-HSA-933542 )
TAK1-dependent IKK and NF-kappa-B activation (R-HSA-445989 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Regulation of Drug Effects of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
ANW-32821 DMMJOZD Phase 2 Advanced glycosylation end product-specific receptor (AGER) affects the abundance of ANW-32821. [9]
------------------------------------------------------------------------------------
16 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [1]
Cisplatin DMRHGI9 Approved Cisplatin decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [2]
Estradiol DMUNTE3 Approved Estradiol increases the expression of Advanced glycosylation end product-specific receptor (AGER). [3]
Testosterone DM7HUNW Approved Testosterone decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [4]
Diclofenac DMPIHLS Approved Diclofenac increases the expression of Advanced glycosylation end product-specific receptor (AGER). [5]
Ethinyl estradiol DMODJ40 Approved Ethinyl estradiol increases the expression of Advanced glycosylation end product-specific receptor (AGER). [3]
Simvastatin DM30SGU Approved Simvastatin decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [6]
Mebendazole DMO14SG Approved Mebendazole increases the expression of Advanced glycosylation end product-specific receptor (AGER). [7]
Estriol DMOEM2I Approved Estriol increases the expression of Advanced glycosylation end product-specific receptor (AGER). [3]
Flutamide DMK0O7U Approved Flutamide increases the expression of Advanced glycosylation end product-specific receptor (AGER). [5]
Trientine DMD2WPG Approved Trientine decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [8]
Resveratrol DM3RWXL Phase 3 Resveratrol decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [9]
Acteoside DM0YHKB Terminated Acteoside decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [11]
Acetaldehyde DMJFKG4 Investigative Acetaldehyde decreases the expression of Advanced glycosylation end product-specific receptor (AGER). [12]
D-glucose DMMG2TO Investigative D-glucose increases the expression of Advanced glycosylation end product-specific receptor (AGER). [13]
methylglyoxal DMRC3OZ Investigative methylglyoxal increases the expression of Advanced glycosylation end product-specific receptor (AGER). [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of Advanced glycosylation end product-specific receptor (AGER). [10]
------------------------------------------------------------------------------------

References

1 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
2 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
3 Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta. 2005 Sep 30;1745(3):300-9. doi: 10.1016/j.bbamcr.2005.03.012. Epub 2005 Apr 12.
4 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
5 Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
6 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
7 Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol Lett. 2014 Jul 3;228(1):13-24. doi: 10.1016/j.toxlet.2014.04.005. Epub 2014 Apr 15.
8 Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-B pathway in a transgenic mouse model of Alzheimer's disease. Antioxid Redox Signal. 2013 Dec 10;19(17):2024-39. doi: 10.1089/ars.2012.5158. Epub 2013 May 3.
9 Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med. 2010 May;25(5):729-34. doi: 10.3892/ijmm_00000398.
10 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
11 Verbascoside inhibits the epithelial-mesenchymal transition of prostate cancer cells through high-mobility group box 1/receptor for advanced glycation end-products/TGF- pathway. Environ Toxicol. 2021 Jun;36(6):1080-1089. doi: 10.1002/tox.23107. Epub 2021 Feb 1.
12 Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
13 Naturally occurring flavonoids attenuate high glucose-induced expression of proinflammatory cytokines in human monocytic THP-1 cells. Mol Nutr Food Res. 2009 Aug;53(8):984-95.
14 Methylglyoxal disturbs the expression of antioxidant, apoptotic and glycation responsive genes and triggers programmed cell death in human leukocytes. Toxicol In Vitro. 2019 Mar;55:33-42.